STERIS plc STE
208.93
0.16
0.08%
as of 25 Sep
- Market cap
- $20.4B
- P/E
- 25.4×
Follow STE
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
STERIS plc (STE) Operating cash flow
STERIS plc's operating cash flow for fiscal 2026 was $1.3B, up 16.8% from $1.1B in fiscal 2025. Over the twelve months to 30 June 2026 it was $1.3B. Over the past ten years it has ranged from $246.0M (fiscal 2015) to $1.3B (fiscal 2026) — the current reading is the highest in ten years. Operating cash flow has risen for 4 consecutive fiscal years. STERIS plc ranks 11th of 149 Medical Devices companies by operating cash flow.
Operating cash flow, annual
Annual
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | $1.3B | 16.84% |
| FY2025 | $1.1B | 17.96% |
| FY2024 | $973.3M | 28.58% |
| FY2023 | $756.9M | 10.53% |
| FY2022 | $684.8M | (0.70%) |
| FY2021 | $689.6M | 16.78% |
| FY2020 | $590.6M | 9.46% |
| FY2019 | $539.5M | 17.89% |
| FY2018 | $457.6M | 7.91% |
| FY2017 | $424.1M | 66.52% |
Quarterly
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $367.1M | 9.45% |
| Mar 2026 | $335.4M | 12.47% |
| Dec 2025 | $298.2M | 3.61% |
| Sep 2025 | $287.8M | (31.48%) |
| 42 more quarters | Free account |
Against its own ten years
Low $246.0M
High $1.3B
Ten-year median
$637.7M
Current reading's percentile
100
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $3.1B |
| PHG Koninklijke Philips N.V. compare | $2.6B |
| GEHC GE HealthCare Technologies Inc. compare | $2.1B |
| DXCM DexCom, Inc. compare | $1.7B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $1.7B |
| STE STERIS plc | $1.3B |
| BIO Bio-Rad Laboratories, Inc. compare | $492.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $492.6M |
| PEN Penumbra, Inc. compare | $277.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on STE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement